3 active not recruiting, 3 completed, 2 recruiting, 1 terminated. 8 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Active not recruiting 2, Completed 2, Recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Active not recruiting 2, Completed 1 |
Follow Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma: new trials by email Literature Review of Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma trials Research Report on Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment Belinostat, Biopsy Procedure, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2023-03-01 | 2026-09-18 |
| Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma Cyclophosphamide, Fludarabine, Mogamulizumab - Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Phase 1 | Recruiting | John Reneau | 12 | 2022-05-06 | 2026-02-10 |
| Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas Parsaclisib, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Walter Hanel | 5 | 2021-09-01 | 2025-01-17 |
| Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas Brentuximab Vedotin, Lenalidomide, Laboratory Biomarker Analysis - CD30-Positive Neoplastic Cells Present, Folliculotropic Mycosis Fungoides | Phase 1 | Withdrawn | City of Hope Medical Center | 2019-03-01 | 2019-04-30 | |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Belinostat, Carfilzomib, Copanlisib Hydrochloride - Breast Adenocarcinoma, Metastatic Breast Carcinoma | Phase 1 | Terminated | Mayo Clinic | 17 | 2018-03-27 | 2025-05-26 |
| Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma Brentuximab Vedotin, Laboratory Biomarker Analysis, Lenalidomide - Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma | Phase 2 | Completed | John Reneau | 26 | 2018-03-16 | 2026-08-13 |
| Study of Pembrolizumab (MK-3475) in Combination With Romidepsin Pembrolizumab, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 39 | 2017-11-14 | 2026-09-30 |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 68 | 2017-09-27 | 2026-08-13 |
| A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm | Phase 1 | Recruiting | Mayo Clinic | 99 | 2017-04-04 | 2026-06-10 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Pharmacological Study, Romidepsin - Glioma, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 37 | 2012-08-03 | 2025-02-07 |
Lymphoma, T-Cell, Cutaneous (10) · Lymphoma, T-Cell (7) · Mycosis Fungoides (5) · Lymphoma, Large-Cell, Anaplastic (4) · Breast Neoplasms (2) · Immunoblastic Lymphadenopathy (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Sezary Syndrome (2) · Adenocarcinoma, Papillary (1) · Carcinoma, Basal Cell (1) · Carcinoma, Basosquamous (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1) · Carcinoma, Signet Ring Cell (1)
Hemic and Lymphatic Diseases (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Lymphatic Diseases (10) · Lymphoproliferative Disorders (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Lymphoma (9) · Lymphoma, Non-Hodgkin (8) · Hematologic Diseases (3) · Leukemia (3) · Lymphoma, T-Cell (3) · Neoplasms by Site (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3)
Depsipeptides (4) · Lactones (4) · romidepsin (4) · Biopsy (3) · Magnetic Resonance Spectroscopy (3) · Nivolumab (3) · Specimen Handling (3) · Brentuximab Vedotin (2) · Cyclophosphamide (2) · Disulfides (2) · Immunoglobulin G (2) · Lenalidomide (2) · belinostat (2) · pembrolizumab (2) · CT-P10 (1)
National Cancer Institute (NCI) (3) · John Reneau (2) · Mayo Clinic (2) · City of Hope Medical Center (1) · M.D. Anderson Cancer Center (1) · Walter Hanel (1)
United States (10) · Canada (1)
Grzegorz S. Nowakowski, M.D. (1) · Jasmine Zain, MD (1) · Jennifer E Amengual (1) · John C Reneau, MD, PhD (1) · John Reneau, MD (1) · Joselle Cook, M.B.B.S. (1) · Nora Bennani, M.D. (1) · Roisin M Connolly (1) · Swaminathan P Iyer, MD (1) · Walter Hanel, MD, PhD (1)
PMID 35175355, PMID 36898933, PMID 39863139
UM1CA186689 (2), UM1CA186716 (2), P50CA186781 (1), R01CA262613 (1), U01CA062505 (1), U01CA069912 (1), U01CA070095 (1), U01CA132123 (1), UM1CA186644 (1), UM1CA186686 (1), UM1CA186690 (1), UM1CA186691 (1), UM1CA186709 (1), UM1CA186717 (1), ZIABC011078 (1)